- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | RAPID MICRO BIOSYSTEMS, INC. - 10-Q, Quarterly Report | 4 | SEC Filings | ||
| Mi | Rapid Micro Biosystems GAAP EPS of -$0.31 misses by $0.06, revenue of $8M beats by $0.4M | 2 | Seeking Alpha | ||
| RAPID MICRO BIOSYSTEMS Aktie jetzt für 0€ handeln | |||||
| Mi | RAPID MICRO BIOSYSTEMS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| Mi | Rapid Micro Biosystems, Inc.: Rapid Micro Biosystems Reports First Quarter 2026 Financial Results | 543 | GlobeNewswire (Europe) | Reports first quarter 2026 total revenue of $8.0 million, representing 11% growth compared to the first quarter of 2025 Placed 6 Growth Direct systems in the first quarter 2026 compared to 3 systems... ► Artikel lesen | |
| 06.05. | Rapid Micro Biosystems, Inc.: Rapid Micro Biosystems to Announce First Quarter 2026 Financial Results on May 13, 2026 | 1 | GlobeNewswire (USA) | ||
| 27.03. | RAPID MICRO BIOSYSTEMS, INC. - 8-K, Current Report | 5 | SEC Filings | ||
| 17.03. | Rapid Micro Biosystems stellt auf KeyBanc-Forum strategische Wachstumspläne vor | 7 | Investing.com Deutsch | ||
| 12.03. | RAPID MICRO BIOSYSTEMS, INC. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 12.03. | RAPID MICRO BIOSYSTEMS, INC. - 10-K, Annual Report | 2 | SEC Filings | ||
| 12.03. | Rapid Micro Biosystems outlines $37M-$41M 2026 revenue target amid record system placements and margin expansion drive | 1 | Seeking Alpha | ||
| 12.03. | Rapid Micro Biosystems: Starker Umsatz, aber höherer Verlust im Q4 2025 - Aktie bricht vorbörslich ein | 8 | Investing.com Deutsch | ||
| 12.03. | Rapid Micro Biosystems reports mixed Q4 results; introduces FY26 outlook | 3 | Seeking Alpha | ||
| 12.03. | Rapid Micro Biosystems, Inc.: Rapid Micro Biosystems Announces Follow-on Multi-System Order from Samsung Biologics to Expand Deployment of Growth Direct Platform | 1.049 | GlobeNewswire (Europe) | LEXINGTON, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the "Company"), an innovative life sciences technology company providing mission critical automation... ► Artikel lesen | |
| 10.03. | Rapid Micro Biosystems, Inc.: Rapid Micro Biosystems to Participate in KeyBanc Capital Markets Healthcare Forum | 2 | GlobeNewswire (USA) | ||
| 24.02. | Rapid Micro Biosystems, Inc.: Rapid Micro Biosystems to Announce Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026 | 1 | GlobeNewswire (USA) | ||
| 12.02. | Rapid Micro Biosystems, Inc.: Rapid Micro Biosystems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 2 | GlobeNewswire (USA) | ||
| 14.01. | After-Hours Biotech Rally: SXTC, RPID, TGTX Lead Gains On Revenue Updates, And FDA Milestones | 651 | AFX News | BEIJING (dpa-AFX) - Several biotechnology and pharmaceutical names posted notable gains in Tuesday's after-hours trading session, driven by corporate updates and investor enthusiasm around clinical... ► Artikel lesen | |
| 13.01. | Rapid Micro Biosystems reports 37% revenue growth in Q4 2025 | 4 | Investing.com | ||
| 13.01. | Rapid Micro Biosystems reports Q4 results | 1 | Seeking Alpha | ||
| 13.01. | Rapid Micro Biosystems reports preliminary fourth quarter revenue | 2 | Seeking Alpha |
1 2 Weiter >>
26 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 28,465 | -0,44 % | Qiagen erhöht Dividende und stellt weitere Aktienrückkäufe in Aussicht | DJ Qiagen erhöht Dividende und stellt weitere Aktienrückkäufe in Aussicht
DOW JONES--Die Aktionäre von Qiagen können sich über eine höhere Dividende freuen. Wie es in der Einladung zur Hauptversammlung... ► Artikel lesen | |
| TANGO THERAPEUTICS | 20,560 | 0,00 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights | First clinical data from PRMT5/RAS(ON) combination trial to be presented in 2026 Cash position of $380 million as of March 31, 2026, with runway into 2028 beyond anticipated key data inflection points... ► Artikel lesen | |
| HCW BIOLOGICS | 1,210 | -0,82 % | HCW Biologics Inc.: HCW Biologics Reports First Quarter 2026 Business Highlights and Financial Results | MIRAMAR, Fla., May 14, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on developing transformative... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 81,09 | -0,06 % | Jefferies raises Apogee Therapeutics stock price target on trial outlook | ||
| PRAXIS PRECISION MEDICINES | 341,89 | -0,20 % | Praxis Precision Medicines, Inc. - 8-K, Current Report | ||
| CG ONCOLOGY | 66,93 | 0,00 % | CG Oncology Inc.: CG Oncology Reports Positive First Results from CORE-008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients | - High CR rates at any time observed in the CIS-containing population with 85.7% and 92.3% in the ITT population and Efficacy Evaluable population, respectively - High-Grade - EFS in the overall intention-to-treat... ► Artikel lesen | |
| EVOTEC | 4,618 | -1,74 % | Evotec zapft den Kapitalmarkt an | Evotec platziert Wandelanleihen über 116,1 Mio. EUR und finanziert damit das Transformationsprogramm "Project Horizon". Die Evotec SE hat sich frisches Kapital über den Wandelanleihemarkt gesichert.... ► Artikel lesen | |
| BIONTECH | 76,40 | -2,98 % | Community Rückblick: wO-User zu BioNTech Quartalsbericht: "Oh wow, die Zahlen sind eine Katastrophe!" | © Foto: picture alliance / Laci Perenyi | Laci PerenyiBioNTech steht nach neuen Quartalszahlen und angekündigten Standortschließungen weiter unter Druck. Hohe Verluste, Umbau des Geschäfts und das Aus... ► Artikel lesen | |
| COGENT BIOSCIENCES | 32,710 | +0,09 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Multiple Presentations at the European Hematology Association (EHA) 2026 Congress | ||
| NUVALENT | 102,40 | +0,10 % | Nuvalent, Inc.: Nuvalent Highlights Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2026 Financial Results | NDA submitted for neladalkib in TKI pre-treated advanced ALK-positive NSCLC
NDA for zidesamtinib in TKI pre-treated advanced ROS1-positive NSCLC under FDA review... ► Artikel lesen | |
| JADE BIOSCIENCES | 23,355 | 0,00 % | Jade Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Update | Interim biomarker-rich Phase 1 data for JADE101 to be featured in an oral session at the 63rd European Renal Association Congress Phase 2 trial of JADE101 in IgA nephropathy patients expected to begin... ► Artikel lesen | |
| RELAY THERAPEUTICS | 12,205 | +0,04 % | H.C. Wainwright is Bullish on Relay Therapeutics, Inc. (RLAY) | ||
| TYRA BIOSCIENCES | 37,070 | +0,08 % | Tyra Biosciences GAAP EPS of -$0.64 | ||
| KYMERA THERAPEUTICS | 82,25 | +0,05 % | Kymera presents KT-621 atopic dermatitis trial data at conferences | ||
| BEAM THERAPEUTICS | 27,945 | +0,05 % | H.C. Wainwright reiterates Beam Therapeutics stock rating at buy |
Das Unternehmen RAPID MICRO BIOSYSTEMS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,020 (+0,97 %) liegt der Kurs bei 2,090 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu RAPID MICRO BIOSYSTEMS INC finden Sie auf Wallstreet Online.